 |
|
 |
|
| Vaccines/mRNA/RNA Tech Strategic Pipeline Review |
|
|
|
Currently updating: Q4 2025
Analysis of the current and historical vaccine research and development (R&D) pipeline is a critical component of any organisation's competitive intelligence effort.
This exercise can inform both internal & external decision makers and input into many processes, including strategic portfolio management, business development and licensing, R&D prioritization and corporate development/investment.
Key challenges with the analysis are that, not only is the vaccine pipeline dynamic, but a historical view requires skilled judgement during curation,
especially when assigning new fields which can produce meaningful outputs.
This Q4 2025 Vaccines/mRNA Strategic Pipeline Review (industry only) contains analysis of >2128 total clinical trials operated by ~270 companies and investigates current and historical vaccine trial
activity by inserting a range of new fields including vaccine type/production system/adjuvant* including mRNA landscape analysis, infectious diseases, chronic conditions or cancer, pathogen/condition (~90 included), market segment,
study duration and company size (Small, Medium and Large) and more.
Using the MS-Excel workbook provided, a range of tabular and graphical outputs help visualize competitive activity [current/past] and investment in various segments/pathogens relative to each other and the academic sector.
These outputs form the basis of a gap analysis or heatmap that could guide future investment especially with regard to new nucleic-based approaches.
A new mRNA vaccine landscape focus section is now included with new and emerging seasonal influenza (monovalent + combination) and RSV programs including mRNA-1010, mRNA-1020/30, mRNA-1073, mRNA-1345, mRNA-1230, mRNA-1045, mRNA-1365 (ModernaTX), PF-07252220, PF07852352, PF-07941314 (Pfizer), GSK4382276A (GSK), and SP0273 MRT5400, MRT5401, CL-0059/CL-0137 (Sanofi). Companies possessing mRNA technologies within the COVID-19 space are considered with an indication of the level of Self-amplifying technologies[SAM] and other novel formats. New entrants such as AstraZeneca/Cansino and an analysis of mRNA programs focused on non-ID areas e.g. oncology is now included.
>>Try a sample
by Microsoft PowerBI
THIS PRODUCT IS A EXECUTIVE PRESENTATION (.pdf) + MS Excel Workbook
Photo Credit: JJ Ying @unsplash, *conducted for major active programs only
To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations).
Please review the TERMS and CONDITIONS of purchase.
|
|
|
|
|
|
